We find that compromising RUNX1 DNA binding using a pharmacological inhibitor that disrupts the interaction between RUNX1 and CBFβ results in loss of the epithelial phenotype and acquisition of mesenchymal properties that are accompanied by changes in expression of associated genes and pathways and represent early events in the onset of breast cancer. This evidence concerns the gene CBFB and breast cancer.